Esperion Therapeutics stock (US2964331002): Nasdaq-listed biotech steady after recent volatility

Esperion Therapeutics shares on Nasdaq traded around the mid-USD 3 range on 06/02/2026 after a volatile start to the year, keeping the United States-based cholesterol-focused biotech in focus for investors following its latest quarterly update and ongoing commercialization efforts.

Esperion Therapeutics shares on the Nasdaq under the ticker ESPR traded around the mid-USD 3 range on 06/02/2026, leaving the United States-based biotech broadly flat on the day after a spell of heightened volatility earlier in 2026, according to Nasdaq trading data as of early afternoon Eastern Time.

The stock recently changed hands at roughly USD 3.14 on the Nasdaq Stock Market on 06/02/2026, compared with a level of about USD 3.70 at the beginning of 2026, implying a year-to-date decline of just over 15% based on MarketBeat data citing Nasdaq pricing as of 06/02/2026.

With its primary listing in the United States and headquarters in Michigan, Esperion Therapeutics remains anchored in the U.S. biotech ecosystem, while German investors can also access the stock via secondary trading venues such as Tradegate where it is quoted in euros alongside its home-market Nasdaq listing in U.S. dollars.

As of: 02/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: ESPR
• Sector/industry: Biopharmaceuticals focused on cardiovascular and metabolic diseases
• Headquarters/country: Ann Arbor, United States
• Core markets: United States and selected international markets via partners
• Key revenue drivers: Cholesterol-lowering therapies including bempedoic acid-based products
• Home exchange/listing venue: Nasdaq (ESPR)
• Trading currency: USD

Esperion Therapeutics: core business model

Esperion Therapeutics develops and commercializes oral, non-statin lipid-lowering medicines, with revenue primarily generated from sales and partnered commercialization of bempedoic acid-based treatments for lowering LDL cholesterol in patients with elevated cardiovascular risk.

Latest quarterly results for Esperion Therapeutics at a glance

In its most recently reported quarter, Esperion Therapeutics highlighted that it continues to focus on the commercial rollout and market penetration of its cholesterol-lowering therapies, with management emphasizing progress in expanding patient access and prescriber adoption based on the latest investor presentation and earnings materials published in 2026 on the companys investor relations website.

While detailed revenue and earnings figures from the latest quarter were discussed in company communications, the overarching message from Esperion Therapeutics was that it is concentrating on driving prescription growth, managing operating expenses, and working with partners to broaden reimbursement coverage, according to commentary from management in its most recent quarterly update and supporting materials released in 2026.

Conclusion

Esperion Therapeutics stock on the Nasdaq remained in the mid-USD 3 range on 06/02/2026 after a choppy start to the year, underscoring investor sensitivity to execution on its cholesterol-lowering portfolio.

The latest quarterly communication from management reinforced a focus on expanding the reach of its bempedoic acid-based products and managing the path toward sustainable profitability, themes that are likely to stay central to the equity story as trading volumes remain elevated compared with historical levels.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.